Jul 02, 2025
Hikma receives FDA approval for TYZAVAN(TM) (Vancomycin Injection, USP) in the US
Aug 20, 2024
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
Aug 15, 2024
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
Feb 18, 2021
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Jan 13, 2021
Hikma's commitment to environmental performance recognised with "A-" rating in 2020 CDP Global Climate Change Report
Oct 20, 2020
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Sep 03, 2020
Hikma receives favourable court ruling for its generic Vascepa®
Aug 26, 2020
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
May 28, 2020
Hikma launches Dicyclomine Hydrochloride Oral Solution
May 22, 2020
Hikma receives FDA approval for its generic Vascepa®
May 12, 2020
Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP
May 11, 2020
Hikma launches employee matching donation campaign to support local US food banks and pantries
May 04, 2020
Hikma Ventures invests in Altoida, Inc., a predictive digital biomarker company using AI and AR to help predict brain diseases with up to 94% accuracy
Mar 04, 2020
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP 30mg/mL, 1mL Fill/2mL Vials Due to the Potential Presence of Small Particulates